SCHEMBL896318

SCHEMBL896318

Cc1nnc(Cl)c(-c2ncc(Cl)cc2Cl)c1-c1ccc(Cl)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.37
HSD11B1 P28845 1/20 0.35
CRHR1 P34998 2/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
PTGS2 P35354 6/20 0.34
PTGS1 P23219 3/20 0.34
KMT2A Q03164 4/20 0.33
MEN1 O00255 3/20 0.33
CACNA2D1 P54289 1/20 0.33
ALDH1A1 P00352 2/20 0.33
ABCC4 O15439 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569381 0.91 CNR2 (0.42) CNR2HSD11B1MAPTKDM4EGRIN2D
SCHEMBL10000738 0.91 CNR2 (0.35) CNR2CRHR1KDM4EPTGS2PTGS1
SCHEMBL10000761 0.90 MAOB (0.40) CNR2HSD11B1CRHR1MAPTKDM4E
SCHEMBL3604528 0.88 CNR2 (0.38) CNR2CRHR1KDM4EPTGS2PTGS1
SCHEMBL3609800 0.88 PTGS2 (0.43) CNR2CRHR1PTGS2PTGS1ABCC4
SCHEMBL13092765 0.88 KMT2A (0.37) CNR2MAPTKDM4EPOLBGRIN2D
SCHEMBL896631 0.87 PTGS2 (0.36) MAPTKDM4EPOLBGRIN2DGRIN3B
SCHEMBL896839 0.85 KMT2A (0.40) CNR2MAPTKDM4EKMT2AMEN1
SCHEMBL10131946 0.84 KDM4E (0.36) MAPTKDM4EPOLBKMT2ACACNA2D1
SCHEMBL3619780 0.84 IDO1 (0.37) CNR2CRHR1PTGS2PTGS1ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598176-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-12-03 US disclosed
US-8258136-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-04 US disclosed
US-8258136-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-04 US disclosed
US-8258136-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-04 US disclosed
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-04-05 US disclosed
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-04-05 US disclosed
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-04-05 US disclosed
EP-1958946-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2011-02-23 EP disclosed
US-20090275589-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-05 US disclosed
US-20090275589-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-05 US disclosed
US-20090275589-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-05 US disclosed
EP-1958946-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF PLPBP, PNPO, PDXK CNR2 502/4885HSD11B1 1661/4885CRHR1 3705/4885
US-20090275589-A1 Pyridazine Compound and Use Thereof PLPBP, PNPO, PDXK CNR2 502/4885HSD11B1 1661/4885CRHR1 3705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.